Search research articles
Contact Us
Filters
Showing results (31-40 of 268) with videos related to
Page
of 27
Sort By:
Journal of Chemotherapy (Florence, Italy)
|
February 4, 2005
Drug discovery strategies: technologies to accelerate translation from target to drug
P Workman
International Journal of Radiation Oncology, Biology, Physics
|
January 1, 1992
Bioreductive mechanisms
P Workman
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 1, 1992
Emerging from a crisis in anticancer drug discovery? Screening versus design: confessions of an optimistic fence-sitter
P Workman
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 1, 1992
Signal transduction inhibitors as novel anticancer drugs: where are we?
P Workman
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1992
Anticancer drug screening and discovery in the 1990s: a European perspective
G Schwartsmann, P Workman
Biochemical Pharmacology
|
August 18, 1992
Lack of enantio-selectivity in the in vitro antitumour cytotoxicity and membrane-damaging activity of ether lipid SRI 62-834: further evidence for a non-receptor-mediated mechanism of action
M Lohmeyer, P Workman
Journal of Chromatography
|
November 16, 1990
Gradient high-performance liquid chromatographic assay for the determination of the novel indoloquinone antitumour agent E09 in biological specimens
M Binger, P Workman
British Journal of Cancer
|
March 1, 1982
Effect of misonidazole or metronidazole pretreatment on the response of the RIF-1 mouse sarcoma to melphalan, cyclophosphamide, chlorambucil and CCNU
P Twentyman, P Workman
Biochemical Pharmacology
|
January 7, 1993
The role of intracellular free calcium mobilization in the mechanism of action of antitumour ether lipids SRI 62-834 and ET18-OMe
M Lohmeyer, P Workman
Cancer Chemotherapy and Pharmacology
|
January 1, 1991
Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069)
M Binger, P Workman
Page
of 27
Search research articles
Search
Showing results (31-40 of 268) with videos related to
Sort By:
Page
of 27
Journal of Chemotherapy (Florence, Italy)
|
February 4, 2005
Drug discovery strategies: technologies to accelerate translation from target to drug
P Workman
International Journal of Radiation Oncology, Biology, Physics
|
January 1, 1992
Bioreductive mechanisms
P Workman
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 1, 1992
Emerging from a crisis in anticancer drug discovery? Screening versus design: confessions of an optimistic fence-sitter
P Workman
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 1, 1992
Signal transduction inhibitors as novel anticancer drugs: where are we?
P Workman
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1992
Anticancer drug screening and discovery in the 1990s: a European perspective
G Schwartsmann, P Workman
Biochemical Pharmacology
|
August 18, 1992
Lack of enantio-selectivity in the in vitro antitumour cytotoxicity and membrane-damaging activity of ether lipid SRI 62-834: further evidence for a non-receptor-mediated mechanism of action
M Lohmeyer, P Workman
Journal of Chromatography
|
November 16, 1990
Gradient high-performance liquid chromatographic assay for the determination of the novel indoloquinone antitumour agent E09 in biological specimens
M Binger, P Workman
British Journal of Cancer
|
March 1, 1982
Effect of misonidazole or metronidazole pretreatment on the response of the RIF-1 mouse sarcoma to melphalan, cyclophosphamide, chlorambucil and CCNU
P Twentyman, P Workman
Biochemical Pharmacology
|
January 7, 1993
The role of intracellular free calcium mobilization in the mechanism of action of antitumour ether lipids SRI 62-834 and ET18-OMe
M Lohmeyer, P Workman
Cancer Chemotherapy and Pharmacology
|
January 1, 1991
Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069)
M Binger, P Workman
Page
of 27